Market Insights
Stool tests are performed to diagnose G.I. tract disorders and aid in the detection of parasite infection, bleeding obstruction, and inflammation. Stool tests can also be used to diagnose colorectal cancer or the presence of pathogens in the G.I. tract, such as rotavirus, C. difficile, and H. pylori. Laboratory tests used for stool testing are either microbial particle-based or antibody-based, which include chemiluminescence immunoassays (CLIA), immunoassays, and molecular diagnostic testing.
The increased prevalence of Clostridium difficile infections and other gastrointestinal diseases drives the global G.I. stool testing market. According to the Centers for Disease Control and Prevention, in 2014, an estimated 14.8 million adults were diagnosed with ulcers and other digestive disorders in the United States. Furthermore, in 2017, 135,430 new cases of colorectal cancer were diagnosed in the country, raising the demand for G.I. stool testing. However, the challenge of accurate testing restrains the market.
The global G.I. stool testing market is segmented based on product type, application, test type, end-user, and geography. Among product types, the reagents segment dominated the global market in 2017 with over 60% of the market share. Among applications, the G.I. tract infections segment led the global market in 2017 owing to the high prevalence of cases and increased awareness regarding gastrointestinal disorders. Based on end-users, hospitals will continue to dominate the market owing to the high procedural load of the tests.
North America is anticipated to lead the global market owing to the high awareness of gastrointestinal disorders and the availability of an evolved healthcare infrastructure. Manufacturers are focusing on emerging markets, including those in Asia-Pacific and Latin America, due to the presence of potential opportunities.
The global G.I. stool testing market is classified as follows:
Global G.I. Stool Testing Market by Product Type, 2016-2026 (in millions of U.S. dollars)
Global G.I. Stool Testing Market by Application (US$ Mn), 2016-2026
- Colorectal Cancer
- Diarrhea
- G.I. tract infections
- Others (poor absorption problems, parasites)
Global G.I. Stool Testing Market by Test Type (US$ Mn), 2016-2026
- Microscopy Tests
- Culture Tests
- Ova and Parasites Examination
- occult blood test
- ELISA Test for Immuno-FOB
- Lateral Flow Immuno-FOB Test
- Immuno-FOB agglutination test
- Guaiac FOB Stool Test
- Stool biomarker tests
- M2-PK stool test
- Cologuard
- Other tests (FIT (Fecal Immunochemical Test), Stool Fat Testing) are available.
End-User Global G.I. Stool Testing Market, 2016-2026 (US$ Mn)
- Hospitals
- Diagnostic Centers and Laboratories
- Research Centers and Academic Institutions
Global G.I. Stool Testing Market by Geography (US$ Mn), 2016-2026
- North America
- Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Key players identified in the G.I. stool testing market include:
Abbott Laboratories, Alere, Inc., Beckman Coulter, Inc., BioMrieux, Inc., Bio-Rad Laboratories, Cenegenics Corporation, DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics Incorporated, and Siemens Healthcare
This report offers:
- A detailed outlook and current dynamics of the global G.I. stool testing market, along with future trends.
- Market estimations of the global G.I. stool testing market for the span of 10 years, from 2016 to 2026
- Global G.I. stool testing market elucidation at the granular level through market segmentation based on various parameters
- Profiling of the key players operating in the G.I. stool testing market, along with graphical positioning of the major players
